Microvolt T-wave alternans and the selective use of implantable cardioverter defibrillators for primary prevention: A cost-effectiveness study

International Journal of Technology Assessment in Health Care

Volumn 25, Issue 2, 2009, Pages 151-160

  Filion, Kristian B ^a   Xie, Xuanqian ^b   Van Der Avoort, Charlotte J ^c   Dendukuri, Nandini ^a,d   Brophy, James M ^b  

^a MCGILL UNIVERSITY   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Arrhythmias; Cost effectiveness; Implantable cardioverter defibrillators; Microvolt T wave Alternans; Primary prevention

Indexed keywords

ANALYSIS MODELS; ARRHYTHMIAS; CARDIAC DEATH; IMPLANTABLE CARDIOVERTER DEFIBRILLATORS; INCREMENTAL COST; MARKOV DECISION; MEDICAL THERAPY; MICROVOLT T-WAVE ALTERNANS; PRIMARY PREVENTION; TEST RESULTS; THIRD PARTIES; TIME HORIZONS;

COST EFFECTIVENESS; COSTS; DEFIBRILLATORS;

SENSITIVITY ANALYSIS;

ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; CLINICAL DECISION MAKING; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DEFIBRILLATOR; HEALTH CARE COST; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE ARRHYTHMIA; HUMAN; MICROVOLT T WAVE ALTERNANS; PATIENT SELECTION; PREDICTION; PRIMARY PREVENTION; QUALITY ADJUSTED LIFE YEAR; SUDDEN DEATH; T WAVE AMPLITUDE; THEORETICAL MODEL; TREATMENT INDICATION; AGED; COMPARATIVE STUDY; ECONOMICS; HEART ARRHYTHMIA; HEART LEFT VENTRICLE FUNCTION; PROBABILITY;

AGED; ARRHYTHMIAS, CARDIAC; COST-BENEFIT ANALYSIS; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; HUMANS; MARKOV CHAINS; QUALITY-ADJUSTED LIFE YEARS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 67549147282     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462309090205     Document Type: Article

References (56)

1. Al-Khatib SM, Anstrom KJ, Eisenstein EL, et al. Clinical and economic implications of the multicenter automatic de- fibrillator implantation trial-II. Ann InternMed. 2005;142:593-600. (Pubitemid 40529955)
2. Amit G, Costantini O, Super DM, Rosenbaum DS. Microvolt T-wave alternans and electrophysiological testing predict different arrhythmia outcomes: Lessons from the alternans before cardioverter defibrillator (ABCD) trial. J Am Coll Cardiol. 2008;51:A18.
3. Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from nearfatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med. 1997;337:1576-1583.
4. Armoundas AA, Hohnloser SH, Ikeda T, Cohen RJ. Canmicrovolt T-wave alternans testing reduce unnecessary defibrillator implantation? Nat Clin Pract Cardiovasc Med. 2005;2:522-528. (Pubitemid 41670343)
5. Bansch D, Antz M, Boczor S, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: The cardiomyopathy trial (CAT). Circulation. 2002;105:1453-1458. (Pubitemid 34263277)
6. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-237. (Pubitemid 40110811)
7. Bigger JT. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. N Engl J Med. 1997;337:1569-1575.
8. Bloomfield DM, Bigger JT, Steinman RC, et al. Microvolt Twave alternans and the risk of death or sustained ventricular arrhythmias in patients with left ventricular dysfunction. J Am Coll Cardiol. 2006;47:456-463.
9. Braga SS, Vaninetti R, Laporta A, Picozzi A, Pedretti RFE. T wave alternans is a predictor of death in patientswith congestive heart failure. Int J Cardiol. 2004;93:31-38. (Pubitemid 38068506)
10. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 2000;17:479-500.
11. Bristow MR, Saxon LA, Boehmer J, et al. Cardiacresynchronization therapy with or without an implantable de-fibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140-2150.
12. Bryant J, Brodin H, Loveman E, Clegg A. Clinical effectiveness and cost-effectiveness of implantable cardioverter defibrillators for arrhythmias: A systematic review and economic evaluation. Int J Technol Assess Health Care. 2007;23:63-70. (Pubitemid 46648301)
13. Buxton M, Caine N, Chase D, et al. A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context. Health Technol Assess. 2006;10:iii-xi, 1. (Pubitemid 44548801)
14. Canadian Institute for Health Information (CIHI). Provincial and territorial government health expenditure by age group, sex and major category. http://www.cihi.ca/cihiweb/dispPage. jsp?cw-page=download-form-e&cw-sku= PTGHEAGSMCPDF& cw-ctt=1&cw-dform=N (accessed September 19, 2007).
15. Chan PS, Stein K, Chow T, et al. Cost-effectiveness of a microvolt T-wave alternans screening strategy for implantable cardioverter-defibrillator placement in the MADIT-II-eligible population. J Am Coll Cardiol. 2006;48:112-121. (Pubitemid 43929211)
16. Chow T, Kereiakes DJ, Bartone C, et al. Prognostic utility of microvolt T-wave alternans in risk stratification of patients with ischemic cardiomyopathy. J Am Coll Cardiol. 2006;47:1820-1827. (Pubitemid 44308234)
17. Chu HT, Cole SR. Bivariate meta-analysis of sensitivity and specificity with sparse data: A generalized linear mixed model approach. J Clin Epidemiol. 2006;59:1331-1332. (Pubitemid 44708615)
18. Cohen RJ. Enhancing specificity without sacrificing sensitivity: Potential benefits of using microvolt T-wave alternans testing to risk stratify the MADIT-II population. Card Electrophysiol Rev. 2003;7:438-442.
19. Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS)-A randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101:1297-1302. (Pubitemid 30158618)
20. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Cost analysis.Methods for the economic evaluation of health care programs. 3rd ed. Oxford: Oxford University Press; 2005:55-102.
21. EckmanMH, Falk RH, Pauker SG. Cost-effectiveness of therapies for patients with nonvalvular atrial fibrillation. Arch Intern Med. 1998;158:1669-1677. (Pubitemid 28371191)
22. EuroQol Group. EQ-5D. http://www.euroqol.org/ (accessed April 20, 2008).
23. Ezekowitz JA, Rowe BH, Dryden DM, et al. Systematic review: Implantable cardioverter defibrillators for adults with left ventricular systolic dysfunction. Ann Intern Med. 2007;147:251-262. (Pubitemid 351664582)
24. Greenberg D, Bakhai A, Cohen DJ. Can we afford to eliminate restenosis? Can we afford not to? J Am Coll Cardiol. 2004;43:513-518. (Pubitemid 38229518)
25. Grimm W, Christ M, Bach J, Muller HH, Maisch B. Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy: Results of the Marburg cardiomyopathy study. Circulation. 2003;108:2883-2891. (Pubitemid 37517816)
26. Hamza TH, van Houwelingen HC, Stijnen T. The binomial distribution of meta-analysis was preferred to model withinstudy variability. J Clin Epidemiol. 2008;61:41-51. (Pubitemid 350236698)
27. Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004;351:2481-2488. (Pubitemid 39603155)
28. Hreybe H, Bedi M, Ezzeddine R, et al. Indications for internal cardioverter defibrillator implantation predict time to first shock and the modulating effect of beta-blockers. Am Heart J. 2005;150:1064. (Pubitemid 41607799)
29. Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350:2151-2158. (Pubitemid 38637995)
30. Klingenheben T, Ptaszynski P. Clinical significance of microvolt T-wave alternans. Herzschrittmacherther Elektrophysiol. 2007;18:39-44. (Pubitemid 46536792)
31. Klingenheben T, Zabel M, D'Agostino RB, Cohen RJ, Hohnloser SH. Predictive value of T-wave alternans for arrhythmic events in patients with congestive heart failure. Lancet. 2000;356:651-652. (Pubitemid 30627594)
32. Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: The Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102:748-754. (Pubitemid 30648765)
33. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization: Tentative guidelines for using clinical and economic evaluations. CMAJ. 1992;146:473-481.
34. Le Heuzey JY, Paziaud O, Piot O, et al. Cost of care distribution in atrial fibrillation patients: The COCAF study. Am Heart J. 2004;147:121-126. (Pubitemid 38037407)
35. Maisel WH, Sweeney MO, Stevenson WG, Ellison KE, Epstein LM. Recalls and safety alerts involving pacemakers and implantable cardioverter-defibrillator generators. JAMA. 2001;286:793-799.
36. Marshall DA, Levy AR, Vidaillet H, et al. Cost-effectiveness of rhythm versus rate control in atrial fibrillation.Ann InternMed. 2004;141:653-661. (Pubitemid 39440011)
37. McGregor M, Chen J. Use of the implantable cardiac defibrillator (ICD) at the McGill University Health Centre (MUHC). A technology assessment. By the McGill University Health Centre, Montreal, Quebec; 2004. http://www.mcgill.ca/ files/tau/icd.pdf (accessed September 15, 2007).
38. Miners A, Cairns J. Probabilistic sensitivity analysis. In: Fox- Rushby J, Cairns J, eds. Economic evaluation (understanding public health). OZGraf.S.A: Open University Press; 2005:171-183.
39. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med. 1996;335(26):1933-1940.
40. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-883. (Pubitemid 34984635)
41. Mushlin AI, Hall WJ, Zwanziger J, et al. The cost-effectiveness of automatic implantable cardiac defibrillators: Results from MADIT. Circulation. 1998;97:2129-2135.
42. O'Brien BJ, Connolly SJ, Goeree R, et al. Cost-effectiveness of the implantable cardioverter-defibrillator - Results from the Canadian Implantable Defibrillator Study (CIDS). Circulation. 2001;103:1416-1421. (Pubitemid 32220634)
43. Organisation for Economic Co-operation and Development. Purchasing power parities (PPPs). http://www.oecd.org/ department/0,3355,en-2649-34357-1-1-1-1-1, 00.html (accessed September 18, 2007).
44. Owens DK, Sanders GD, Harris RA, et al. Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death. Ann Intern Med. 1997;126:1-12.
45. Public Health Agency of Canada. Major chronic diseases mortality by age group. http://dsol-smed.phac-aspc.gc.ca/dsolsmed/ mcd-smcm/d-age-e.html (accessed September 20, 2007).
46. Sakabe K, Ikeda T, Sakata T, et al. Comparison of T-wave alternans and QT interval dispersion to predict ventricular tachyarrhythmia in patients with dilated cardiomyopathy and without antiarrhythmic drugs: A prospective study. Jpn Heart J. 2001;42:451-457. (Pubitemid 33040835)
47. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med. 2005;353:1471-1480.
48. St. Jude Medical. ICD implantation. http://www.sjm.com/procedures/ procedure.aspx?name=ICD+Implantation§ion= FAQ#109 (accessed September 20, 2007).
49. Statistics Canada. Consumer price index (CPI). http://www. statcan.ca/english/Subjects/Cpi/cpi-en.htm (accessed September 20, 2007).
50. Stiell IG, Wells GA, Demaio VJ, et al. Modifiable factors associated with improved cardiac arrest survival in a multicenter basic life support/defibrillation system: OPALS study phase I results. Ann Emerg Med. 1999;33:44-50.
51. Strickberger SA, Hummel JD, Bartlett TG, et al. Amiodarone versus implantable cardioverter-defibrillator: Randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia - AMIOVIRT. J Am Coll Cardiol. 2003;41:1707-1712.
52. Teng J, Mayo NE, Latimer E, et al. Costs and caregiver consequences of early supported discharge for stroke patients. Stroke. 2003;34:528-536. (Pubitemid 36206360)
53. Van Der Avoort CJ, Filion KB, Dendukuri N, Brophy JM. Microvolt T-wave alternans as a predictor of mortality and severe arrhythmias in patientswith left-ventricular dysfunction: Asystematic review and meta-analysis. BMC Cardiovasc Disord. 2009 Jan 28; 9:5. [Epub ahead of print]
54. Verrier RL, Kumar K, Josephson ME. The frustrating search for arrhythmia risk stratifiers in heart failure due to nonischemic cardiomyopathy: Does T-wave alternans testing help? J Am Coll Cardiol. 2007;50:1905-1906.
55. Wilkoff BL, Hess M, Young J, Abraham WT. Differences in tachyarrhythmia detection and implantable cardioverter defibrillator therapy by primary or secondary prevention indication in cardiac resynchronization therapy patients. J Cardiovasc Electrophysiol. 2004;15:1002-1009. (Pubitemid 39281528)
56. Yao GQ, Freemantle N, Calvert MJ, et al. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. Eur Heart J. 2007;28:42-51. (Pubitemid 46134956)